NCT05068635 is a clinical trial in Gastric Cancer, sponsored by Sylvestre KABURA.

Who is sponsoring NCT05068635?

NCT05068635 is sponsored by Sylvestre KABURA.

What condition does NCT05068635 study?

NCT05068635 studies Gastric Cancer.

Is NCT05068635 still recruiting?

NCT05068635 is currently completed. Last updated 6 October 2021.

Last reviewed 2021-10-06 · How we verify

NCT05068635

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of the Efficacy of Distal Gastrectomy for the Treatment of Gastric Cancer (a Case Series)

Completed Last updated 6 October 2021

What this trial tests

trial in Gastric Cancer in 30 participants. Completed in 31 August 2021.

Timeline

1 January 2013

Primary endpoint
31 December 2017

31 August 2021

Quick facts

Lead sponsor	Sylvestre KABURA
Status	Completed
Study type	OBSERVATIONAL
Enrollment	30
Start date	1 January 2013
Primary completion	31 December 2017
Estimated completion	31 August 2021

Conditions studied

Gastric Cancer — all drugs for Gastric Cancer →

Sponsor

Sylvestre KABURA

Who can join

15 and older, any sex, with Gastric Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Case series of a retrospective study of patients operated for distal adenocarcinoma of the stomach, either by total gastrectomy or distal gastrectomy at Ibn Rochd University Hospital in Casablanca, with the analysis of outcome of patients on a follow up periode of three years and eight months.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Gastric Cancer

Currently open trials in the same condition.

NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer · recruiting
NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting

Other Sylvestre KABURA trials

Trials by the same sponsor.

NCT05186402 — Predictive Factors of Morbidity and Mortality and Overall Survival of Patients With Gastric Cancer : a Case Series · completed
NCT04983056 — Management of Fournier Gangrene at Ibn Rochd University Hospital Center · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05068635 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sylvestre KABURA
Last refreshed: 6 October 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05068635.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing